The Latest Breaking News on After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

An experimental drug appears to slow cognitive decline in people with early onset Alzheimer’s.

After decades of failure in Alzheimer’s disease research, scientists are buoyed by new findings that could mark a turning point in the field, offering hope that treatment may someday slow the grim deterioration of the brain.

The first drug that can slow the rate of decline in Alzheimer’s patients has been found. The experimental drug, called lecanemab, is an antibody that targets the toxic clumps of amyloid protein associated with the mind-robbing disease. While these results are cause for celebration, there are still significant questions about…

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Lecanemab has been shown in trials to slow the progress of early-stage Alzheimer's by 27%

Researchers are optimistic about future management of the disease thanks to a trial drug

New drug proven to slow onset of degenerative brain disease as scientists hail ‘breakthrough’

As trial results bring hope of an effective treatment, Lisa Salmon asks The Alzheimer’s Society what it means for people right now.

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.